Novo Ventures leads a $32m Series A into US-based biotechnology company Allakos for the development of antibody therapeutics for inflammatory diseases, in a round joined by Roche Venture Fund.
Novo Ventures, the corporate venturing-like unit of Denmark-based medical foundation Novo, has led a $32m Series A round into Allakos. There was also participation from life sciences venture capital firms Alta Partners, RiverVest Venture Partners and the Roche Venture Fund, the corporate venturing unit of the Switzerland-based pharmaceutical company.
Peter Moldt, partner at Novo Ventures, Robert Alexander, Director at Alta Partners and John McKearn, managing director at RiverVest Venture Partners, will join Allakos’ board.
Peter Moldt commented: “We…
